biokine_amir

About Amir Caspi

This author has not yet filled in any details.
So far Amir Caspi has created 58 blog entries.

Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE

BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer.
Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% disease control rate out of 22 currently evaluable patients. Median duration of clinical benefit for all 17 patients with disease control […]

December 13th, 2019|Clinical Program BL8040, Recent News|

BioLineRx Presents Preclinical Data From Triple Combination of BL-8040

BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with an […]

November 5th, 2019|Clinical Program BL8040, Recent News|

BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

TEL AVIV, Israel, March 27, 2019 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the  GENESIS trial, a double-blind, placebo-controlled Phase […]

March 27th, 2019|Clinical Program BL8040, Recent News|

BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones. Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter.

October 3rd, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization

Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial.

August 7th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

x30-50 patients in additional arm will be investigated under the collaboration. Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned.

July 30th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted

May 17th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia

Patent valid through March 2034, with up to five years’ patent term extension

May 16th, 2018|Clinical Program BL8040|

BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

January 23rd, 2018|Clinical Program BL8040|

BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients

Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients

December 21st, 2017|Clinical Program BL8040|